Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.
Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle
Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers
In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.
Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
PRB-5069 |
Cell Biolabs |
96 assays |
EUR 686.4 |
Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
PRB-5069-5 |
Cell Biolabs |
5 x 96 assays |
EUR 2739.6 |
Cancer Antigen 15-3 MUC 1 Antigen (Human Milk) |
VAng-Cr3871-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
Paraffin Tissue Section - Human Breast Tumor: Lobular carcinoma |
T2235086-3 |
Biochain |
5 slides |
EUR 308.4 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody |
20-abx148333 |
Abbexa |
|
|
|
BSA (Standard Grade) |
30-AB70 |
Fitzgerald |
1 kg |
EUR 1078.8 |
Description: Standard Grade Bovine Serum Albumin (99% pure) |
Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid) |
VAng-Cr3872-10kU |
Creative Biolabs |
10 kU |
EUR 1363.2 |
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid. |
Cancer Antigen CA 15-3 Protein (Human Fluids) |
VAng-Wyb8628-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: CA 15-3 (Breast Cancer Antigen), Cancer antigen from Human Fluids, 12.240 kU/mL. |
Cancer Antigen CA 15-3 Protein (Human Milk) |
VAng-Wyb8631-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: CA 15-3 (Breast Cancer Antigen), Antigen Grade, Cancer antigen from Human Milk, 33.0 kIU/mL. |
Breast Cancer Exosome |
P141-BR |
101Bio |
- |
Ask for price |
Paraffin Tissue Section - Human Brain Tumor: Astrocytoma Grade III |
T2235035-3 |
Biochain |
5 slides |
EUR 308.4 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Cancer Antigen 15-3 (CA15-3) (human) ELISA Kit |
K4804-100 |
Biovision |
100 assays |
EUR 1000.8 |
|
Description: Sensitive, Colorimetric Assay |
Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium |
9-46027 |
CHI Scientific |
5 x 100 ml |
Ask for price |
Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells |
9-80027 |
CHI Scientific |
1 x 100 ml |
Ask for price |
Breast Cancer Exosome RNA |
P241-BR |
101Bio |
- |
Ask for price |
Fluorescent Exosome Standard (Urine ) |
ESF-15 |
Creative Biolabs |
100 µg |
EUR 2067.6 |
Description: Fluorescent exosomes are labeled with green dye, which offer a stable fluorescent labeling. |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
DLR-CA15-3-Hu-48T |
DL Develop |
48T |
EUR 574.8 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
DLR-CA15-3-Hu-96T |
DL Develop |
96T |
EUR 745.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RDR-CA15-3-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 600 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RDR-CA15-3-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 830.4 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RD-CA15-3-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 573.6 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RD-CA15-3-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 794.4 |
99445-15 DCT 15 X 85MM |
99445-15 |
CORNING |
250/pk |
EUR 116.4 |
Description: Disposable Culture Tubes; DCT's, CGW |
Proteinase K, Recombinant, Standard Grade |
9250-100 |
Biovision |
|
EUR 124.8 |
Proteinase K, Recombinant, Standard Grade |
9250-10G |
Biovision |
|
EUR 4627.2 |
Proteinase K, Recombinant, Standard Grade |
9250-1G |
Biovision |
|
EUR 548.4 |
Proteinase K, Recombinant, Standard Grade |
9250-500 |
Biovision |
|
EUR 314.4 |
Proteinase K, Recombinant, Standard Grade |
9251-100 |
Biovision |
|
EUR 1266 |
Proteinase K, Recombinant, Standard Grade |
9251-25 |
Biovision |
|
EUR 352.8 |
Proteinase K, Recombinant, Standard Grade |
9251-5 |
Biovision |
|
EUR 144 |
Cancer Antigen 242 Antigen |
VAng-Cr3876-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration. |
Cancer Antigen 50 Antigen |
VAng-Cr3877-50kU |
Creative Biolabs |
50 kU |
EUR 6642 |
Description: Cancer Antigen 50 Antigen, Host/Source: Human Cell Culture. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
CA 15-3, Human Breast Adenocarcinoma |
P1435-1 |
Biovision |
|
EUR 130.8 |
CA 15-3, Human Breast Adenocarcinoma |
P1435-5 |
Biovision |
|
EUR 288 |
Polystyrene Particle Size Standard |
PPS-3 |
Spherotech |
mL |
EUR 152.4 |
Description: Please reffer to the technical data sheet for more detail information for this item. Our dedicated team would be happy to assist you via live chat, email or phone. |
Inactivated CMV Grade 3 Antigen |
VAng-Lsx0038-1mg |
Creative Biolabs |
1 mg |
EUR 2503.2 |
Description: CMV Grade 3, natural protein. |
Inactivated MuV Grade 3 Antigen |
VAng-Lsx0411-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: MuV grade 3, native protein. |
Inactivated Rotavirus Grade 3 Antigen |
VAng-Lsx0469-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Rotavirus Grade 3, native virus. |
Inactivated RuV Grade 3 Antigen |
VAng-Lsx0476-1mL |
Creative Biolabs |
1 mL |
EUR 474 |
Description: RuV Grade 3, natural protein. |
Breast Cancer Metastasis Suppressor 1 |
PR27265 |
Neuromics |
2 ug |
EUR 229.2 |
Breast Tumor Kinase antibody |
70R-31875 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Breast Tumor Kinase antibody |
Breast Tumor Kinase antibody |
70R-33385 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Breast Tumor Kinase antibody |
Breast Tissue Lysate (Tumor) |
1713-01 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1713-02 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-01 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-02 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-03 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-04 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-05 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-06 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-07 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Membrane Tumor Lysate |
XBL-10499 |
ProSci |
0.1 mg |
EUR 752.1 |
Description: Human breast tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human breast tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated breast tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated breast tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
Cancer Antigen 72-4 Antigen |
VAng-Cr3878-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 72-4 Antigen, Host/Source: Metastatic Liver. The purity is ~65% by SDS-PAGE. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx171475 |
Abbexa |
|
|
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
20-abx133658 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx129227 |
Abbexa |
-
EUR 510.00
-
EUR 159.60
-
EUR 1446.00
-
EUR 693.60
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
20-abx013807 |
Abbexa |
-
EUR 376.80
-
EUR 117.60
-
EUR 477.60
-
EUR 594.00
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
abx025588-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
abx025588-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx324781 |
Abbexa |
|
|
|
Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) |
4-RPG768Hu01 |
Cloud-Clone |
-
EUR 601.69
-
EUR 284.40
-
EUR 1926.34
-
EUR 722.11
-
EUR 1324.22
-
EUR 477.60
-
EUR 4635.84
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Breast Cancer Anti-Estrogen Resistance 3 expressed in: E.coli |
Human CA15-3 Antigen Grade Protein |
abx060972-250kU |
Abbexa |
250 kU |
EUR 2380.8 |
|
Inactivated PIV-3 Grade 2 Antigen |
VAng-Wyb3637-1mL |
Creative Biolabs |
1 mL |
EUR 1363.2 |
Description: Parainfluenza virus type 3 (strain C243) Grade 2, natural antigen |
Inactivated HSV-1 Grade 3 Antigen |
VAng-Lsx0293-1mg |
Creative Biolabs |
1 mg |
EUR 1786.8 |
Description: HSV Type 1 Grade III, native antigen. |
Inactivated HSV-2 Grade 3 Antigen |
VAng-Lsx0302-1mg |
Creative Biolabs |
1 mg |
EUR 1786.8 |
Description: HSV Type 2 Grade III, native antigen. |
Breast Cancer Metastasis Suppressor 1 Protein |
20-abx263402 |
Abbexa |
-
EUR 1930.80
-
EUR 393.60
-
EUR 276.00
|
|
|
Autobioluminescent Human Breast Cancer Cells (MCF7) |
ASE-5903 |
Applied StemCell |
1 ml |
EUR 2490 |
Description: 6 month |
Autobioluminescent Human Breast Cancer Cells (T47D) |
ASE-5904 |
Applied StemCell |
1 ml |
EUR 2490 |
Description: 6 month |
Human Breast Cancer Signaling Primer Library |
HBRCA-I |
Real Time Primers |
1 set |
EUR 657.6 |
Breast Cancer Anti-Estrogen Resistance 1 |
PR27245 |
Neuromics |
2 ug |
EUR 229.2 |
anti-Breast cancer suppressor candidate 1 |
YF-PA24096 |
Abfrontier |
50 ul |
EUR 400.8 |
Description: Mouse polyclonal to Breast cancer suppressor candidate 1 |
anti-Breast cancer suppressor candidate 1 |
YF-PA12974 |
Abfrontier |
50 ul |
EUR 435.6 |
Description: Mouse polyclonal to Breast cancer suppressor candidate 1 |
anti-Breast cancer suppressor candidate 1 |
YF-PA12975 |
Abfrontier |
50 ug |
EUR 435.6 |
Description: Mouse polyclonal to Breast cancer suppressor candidate 1 |
Prostate Specific Antigen Std Grade Antigen |
VAng-Cr3891-1mg |
Creative Biolabs |
1 mg |
EUR 604.8 |
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation. |
CEA Antigen Grade Protein |
abx060976-05mg |
Abbexa |
0.5 mg |
EUR 1161.6 |
|
CEA Antigen Grade Protein |
abx060977-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
9998 SCREW CAP 415/15 |
9998-15 |
CORNING |
288/pk |
EUR 237.6 |
Description: General Apparatus; Stoppers |
Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues |
Z7020007 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Human Cancer Antigen CA15-3 Protein |
abx060965-50kU |
Abbexa |
50 kU |
EUR 3150 |
|
Cancer Antigen 125 Antigen (Human Adenocarcinoma) |
VAng-Cr3868-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography. |
Cancer Antigen 125 Antigen (Ascites Fluid) |
VAng-Cr3870-10kU |
Creative Biolabs |
10 kU |
EUR 1132.8 |
Description: Cancer Antigen 125 Antigen, Host/Source: Ascites Fluid. The purity is ≥ 95% by SDS-PAGE. |
Cancer Antigen CEA Antigen (Human Fluids) |
VAng-Wyb8644-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Carcinoembryonic Antigen, Calibrator Grade, Cancer antigen from Human Fluids, 1.13 mg/mL. |
Breast Tumor Kinase Blocking Peptide |
AF4768-BP |
Affbiotech |
1mg |
EUR 234 |
Breast Tumor Kinase antibody (Tyr447) |
70R-33384 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Breast Tumor Kinase antibody (Tyr447) |
Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
abx061590-100kU |
Abbexa |
100 kU |
EUR 1446 |
|
Vitamin A Reference Standard (USP grade powder) |
51R-U716002 |
Fitzgerald |
10 pack |
EUR 619.2 |
Description: Vitamin A Reference Standard (USP grade powder) chemical reference substance |
Anti-Rabbit Whole Serum | GWS-15 |
GWS-15 |
Immunology Consultants Laboratory |
1.0 mL |
EUR 130 |
Description: Anti-Rabbit Whole Serum | GWS-15 | Immunology Consultants Laboratory Host: Goat Format: Whole Serum Product Type: Primary Antibody Antibody Clonality: Polyclonal |
Liquid Wicks, Size 15, 200 /pk |
W-15 |
MiTeGen |
200 WICKS |
EUR 22 |
|
Description: Liquid Wicks, Size 15, 200 /pk |
Cancer of the breast, 75 cases (1.1mm), set 3 |
BRC1503 |
Pantomics |
1 |
EUR 300 |
Description: Breast cancer tissue array, set 3, non-overlapping with BRC1501, BRC1502, BRC1504 to BRC15011,150 cores from normal/benign (5 cases) and cancer (70 cases) tissues in duplicates with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Protein |
20-abx168253 |
Abbexa |
-
EUR 844.80
-
EUR 343.20
-
EUR 2598.00
-
EUR 994.80
-
EUR 594.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
20-abx134976 |
Abbexa |
-
EUR 427.20
-
EUR 644.40
-
EUR 260.40
|
|
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
abx010337-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
abx432398-200ul |
Abbexa |
200 ul |
EUR 460.8 |
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
abx218562-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
Breast Cancer Estrogen Resistance 3 (BCAR3) Polyclonal Antibody (Human) |
4-PAG768Hu01 |
Cloud-Clone |
-
EUR 296.40
-
EUR 3012.00
-
EUR 750.00
-
EUR 372.00
-
EUR 256.80
|
- 100ul
- 10ml
- 1ml
- 200ul
- 20ul
|
|
Description: A Rabbit polyclonal antibody against Human Breast Cancer Estrogen Resistance 3 (BCAR3) |
Paraffin Tissue Section - Human Pancreas Tumor: Islet Cell Tumor |
T2235188-3 |
Biochain |
5 slides |
EUR 308.4 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Recombinant Human IL-15 Protein |
PROTP40933-3 |
BosterBio |
10ug |
EUR 380.4 |
Description: IL-15 is an immunomodulating cytokine that stimulates the proliferation of T lymphocytes and shares many biological properties with IL-2. IL-15 exerts its biological activites primarily on T cells. It is also essential in the development, survival and activation of NK cells. Increased expression of IL-15 has been implicated with rheumatoid arthritis, inflammatory bowel disease and diseases affiliated with retroviruses HIV and HTLV-I. Human IL-15 is biologically active on mouse cells as measured by the dose-dependent stimulation of the proliferation of mouse CTLL cells. Recombinant human IL-15 is a 12.9 kDa protein consisting of 114 amino acid residues. |
Swine IL-15 Recombinant Protein |
R00212-3 |
BosterBio |
5ug/vial |
EUR 310.8 |
Description: Interleukin-15 (IL-15) is a cytokine with structural similarity to IL-2 that is secreted by mononuclear phagocytes following infection by virus(es). This cytokine induces cell proliferation of natural killer cells. Swine IL-15 Recombinant Protein is purified interleukin-15 produced in yeast. |
Paraffin Tissue Section - Human Breast Tumor: Male Breast Hyperplasia |
T2235086-4 |
Biochain |
5 slides |
EUR 308.4 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Paraffin Tissue Section - Human Breast Tumor: Medullarycarcinoma of Breast |
T2235086-5 |
Biochain |
5 slides |
EUR 308.4 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Inactivated MuV Grade 3 Antigen (Strain Enders) |
VAng-0619Lsx-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: MuV (Strain Enders) grade 3, native protein. 0.45 mg/mL. |
Human Breast cancer metastasis-suppressor 1 (BRMS1) |
1-CSB-RP048144h |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human Breast cancer metastasis-suppressor 1(BRMS1),partial expressed in E.coli |
Cancer of the breast, 102 cases (1.5mm) |
BRC1021 |
Pantomics |
1 |
EUR 300 |
Description: Breast cancer tissue array, 102 cases of normal/benign (5 cases) and cancer (97 cases) tissues, with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Cancer of the breast, 228 cases (1.1mm) |
BRC2281 |
Pantomics |
1 |
EUR 552 |
Description: Breast cancer tissue array containing 8 cases of normal/benign conditions and 220 cases of cancers with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Cancer of the breast, 49 cases (2mm) |
BRC491 |
Pantomics |
1 |
EUR 228 |
Description: Breast cancer tissue array, non-overlapping with BRC711, 49 cases of normal/benign and cancer tissues with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Cancer of the breast, 71 cases (1.1mm) |
BRC711 |
Pantomics |
1 |
EUR 228 |
Description: Breast cancer tissue array, non-overlapping with BRC491, 71 cases of normal/benign and cancer tissues with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Breast cancer-overexpressed gene 1 protein Antibody |
48092-100ul |
SAB |
100ul |
EUR 399.6 |
Breast cancer-overexpressed gene 1 protein Antibody |
48092-50ul |
SAB |
50ul |
EUR 286.8 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx104049 |
Abbexa |
-
EUR 493.20
-
EUR 159.60
-
EUR 1378.80
-
EUR 678.00
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx104050 |
Abbexa |
-
EUR 526.80
-
EUR 159.60
-
EUR 1496.40
-
EUR 710.40
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx104051 |
Abbexa |
-
EUR 493.20
-
EUR 159.60
-
EUR 1378.80
-
EUR 678.00
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx171476 |
Abbexa |
|
|
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx171477 |
Abbexa |
|
|
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx175628 |
Abbexa |
|
|
|
Breast Cancer Cell Protein 2 (BRCC2) Antibody |
20-abx141388 |
Abbexa |
-
EUR 444.00
-
EUR 727.20
-
EUR 360.00
|
|
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx130340 |
Abbexa |
-
EUR 526.80
-
EUR 159.60
-
EUR 1479.60
-
EUR 710.40
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx129675 |
Abbexa |
-
EUR 510.00
-
EUR 159.60
-
EUR 1412.40
-
EUR 693.60
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx129746 |
Abbexa |
-
EUR 360.00
-
EUR 159.60
-
EUR 961.20
-
EUR 510.00
-
EUR 309.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx008216 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx008217 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
abx030985-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
abx030985-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
abx230960-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Breast Cancer Anti-Estrogen Resistance 1 Protein |
20-abx262743 |
Abbexa |
-
EUR 393.60
-
EUR 7676.40
-
EUR 276.00
|
|
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx327442 |
Abbexa |
|
|
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx328607 |
Abbexa |
|
|
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx241361 |
Abbexa |
|
|
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx241362 |
Abbexa |
|
|
|
SNCG (breast cancer-specific protein 1) Antibody |
BF0110 |
Affbiotech |
200ul |
EUR 540 |
Anti-Human Breast Cancer Resistance Protein antibody |
STJ16100907 |
St John's Laboratory |
1 mL |
EUR 573.6 |
Anti-Mouse Breast Cancer Resistance Protein antibody |
STJ16100917 |
St John's Laboratory |
1 mL |
EUR 573.6 |
Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2) |
4-RPB364Hu01 |
Cloud-Clone |
-
EUR 636.10
-
EUR 294.00
-
EUR 2055.36
-
EUR 765.12
-
EUR 1410.24
-
EUR 501.60
-
EUR 4958.40
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Breast Cancer Susceptibility Protein 2 expressed in: E.coli |
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.